The development of EIDD-2801 has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), under contract numbers HHSN272201500008C and 75N93019C00058, and from the Defense Threat Reduction Agency (DTRA), under contract numbers HDTRA1-13-C-0072 and HDTRA1-15-C-0075, for the treatment of Influenza, coronavirus, chikungunya, and Venezuelan Equine Encephalitis Virus.
About Ridgeback
Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman owned biotechnology company focused on orphan and infectious diseases. Initial funding for Ridgeback Biotherapeutics originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place.
Ridgeback has exclusively licensed DRIVE's EIDD-2801
Ridgeback Biotherapeutics will be responsible for advancing this promising therapeutic through clinical development and ensuring that EIDD-2801 is available during the current pandemic.
So Ridgeback is responsible for "ensuring that the drug will be available during the current pandemic." Do they have the resources and capability to actually DO that?
Two years ago my son in Puerto Rico told me the PR Gov. was recommending Vitamin C to fight Zika and Chikungunya. He said VItamin C was disappearing from store shelves.